Merck expands newest Biologics Testing Center in Shanghai

Merck, a leading science and technology company, has completed the second phase of its new EUR 29 M Biologics Testing Center in China adding 1500 sq m to the lab, which opened in 2022. These are the first biosafety laboratories for Merck in this market, enabling clients to locally access a broad range of testing services for cell line characterization and lot release from pre-clinical development to commercialization. The first phase of investment provides testing services for viral clearance studies, a critical step in drug development. The second phase adds capabilities for cell line characterization that support biopharma customers to ensure the safety, purity, and identity of their cell banks. The testing centre also offers cGMP-compliant lot release testing for unprocessed and purified bulk harvest to meet requirements for biologics entering preclinical and clinical studies, as well as licensed biologics. With the completion of phase two of the facility, Merck now offers a broad range of biosafety testing services for monoclonal antibodies, other recombinant proteins, and cell and gene therapies. The Shanghai facility joins Merck's global biosafety testing network with sites in Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA, and shares the same global expertise, standards, and quality systems. Merck's BioReliance testing services portfolio offers clients leading innovation to ensure the safety and quality of the biopharma industry's supply chain. As a leader in the biosafety testing industry, Merck has more than 1000 clients globally with industry-leading portfolio breadth for major modalities (mAbs, ADCs, CGT, mRNA, and vaccines). Original source: Sigma-Aldrich, website: http://www.sigmaaldrich.com/, Copyright Sigma-Aldrich Co LLC 2023.
investment; research and development; cell therapies; gene therapies; monoclonal antibodies; therapeutic proteins; [...]